IS Pharma Share Discussion Threads

[investinggarden] 08/7/2009 12:15

Strong Buy recommendation on Growth Company Investor

[asp5] 25/6/2009 09:35

I believe this company will significantly outperform the market over the coming years

A quick look at just 3 of its products provides a good illustration:

Mkt Size
Haemopressin 60M
Aloxi 40M
Isoplex 45M (conservative EU extrapolation based of uk mkt size)

Total 145M

The company seems comfortable with a 35% mkt share for each of these products.

This translates to a likely future turnover of 50M, for products that have very low risk (all have regulatotry approval & are in the process of being rolled out, plus they operate in niches that big Pharma are not focused on).

The next few years will be characterised by strong organic growth in a defensive sector that is less exposed to the credit crunch than many others.

The results over the last 2 years have been very solid. As management continue to deliver then I beleive the shares will be re-rated accordingly.

[daytraders] 25/6/2009 08:25

Piper Jaffray initiated its coverage of IS Pharma (ISPH), saying the firm has been transformed from a struggling drug re-formulations firm into a profitable and growing specialist pharmaceuticals and medical devices company. "We believe its smart marketing approach and ability to identify and capitalise on niche product opportunities below the radar screen of its larger competitors will enable it to deliver substantial growth in sales and profitability in the next few years," commented the broker, which has a 'buy' stance and a 110p price target for the shares. "We expect the shares to be driven higher as pan-European launches of Variquel/Haemopressin drive continued growth in revenue and profits," concluded the broker. IS Pharma shares finished 0.5p lower at 82p.

[daytraders] 24/6/2009 20:25

thx geraldus.

[geraldus] 24/6/2009 20:15

Tipped as a strong buy on Growth Company Investor site last Monday and mentioned as a tiddler to watch by the Times stating that broker Piper Jaffray has a 110p price target. - G.Spotts.

[daytraders] 22/6/2009 07:57

Great news guys

RNS Number : 2391U IS Pharma PLC 22 June 2009

22 June 2009

IS Pharma plc ('IS Pharma' or the 'Company')

Launch of Variquel* (Haemopressin®)

IS Pharma plc (LSE: ISPH), the international speciality pharmaceutical company, is pleased to announce the commercial launch of Variquel in the UK and Ireland. This significant event in the UK marks the first of the major marketing authorisations expected across Europe following the recently announced successful completion of European Mutual Recognition Procedure. The earlier than expected commercial launch in the UK will enable sales of Variquel to commence immediately. We expect commercialisation of the brand across the remaining 12 European territories will have commenced substantially during the current financial year.

Variquel is a key global brand for IS Pharma which has a global market estimated at between £50 million - £70 million. Across Europe, Variquel has been indicated for the treatment of bleeding oesophageal varices. In the US, Lucassin® (Variquel in the US) has recently been granted Priority Review as well as Orphan Drug status and Fast Track designation by the U.S. Food and Drug Administration for the treatment of hepatorenal syndrome (HRS) Type 1.

Under the terms of the Speciality European Pharma International AG acquisition which was completed in April 2008, the receipt of the UK marketing authorisation has resulted in a £2 million milestone being paid to Speciality European Pharma Limited.

Tim Wright, CEO of IS Pharma, said:

"The launch of Variquel in the UK is a major milestone towards the commercialisation of the brand across Europe. The commercial launch coming so close after receiving the marketing authorisation from the UK regulatory authority (MHRA) highlights the ability of IS Pharma to rapidly bring to market its key brands. We now have distributors in place across Europe ready to replicate the UK launch the moment marketing authorisations are received. The continued regulatory progress of the brand in the US is also very encouraging."

End-

[daytraders] 19/6/2009 17:03

nice buying again today inc a 50,000 trade.

[gogoneko] 18/6/2009 20:00

asp5,

Thanks for the info, I was wondering about timescales.

Nice bit of news to support the share price.

[daytraders] 18/6/2009 16:20

nice buying today for this share.

[asp5] 18/6/2009 11:02

This status obligates FDA to a goal of acting on the NDA within six-months from the date of submission. So looks like everything on track for approval around end of year.

With Orphan drug status this product will not have any competition in the US for at least 7 years !!

In my view & as recent results have shown ISPH are now in a period (next few years) of strong organic bottom line growth.

[daytraders] 18/6/2009 07:56

RNS Number : 0773U
IS Pharma PLC
18 June 2009



18 June 2009

IS Pharma plc ('IS Pharma')

FDA ACCEPTS FINAL SECTION OF NDA FILING FOR LUCASSIN®

IS Pharma plc (AIM: ISPH), the specialist hospital medicines group, is pleased to announce that Orphan Therapeutics, LLC ('Orphan Therapeutics'), it's North American licensee for Variquel®/Haemopressin® (Lucassin® in the US), has been notified that the U.S. Food and Drug Administration (FDA) has accepted the final section of the New Drug Application (NDA) filing by Orphan Therapeutics, LLC and Ikaria Holdings, Inc. seeking marketing approval for Lucassin® (terlipressin for injection) for the treatment of hepatorenal syndrome (HRS) Type 1. Furthermore, Lucassin has been granted Priority Review, as well as Orphan Drug status and Fast Track designation.

Following marketing approval, Orphan Therapeutics will transfer the North American rights to Ikaria Holdings, Inc., which will then be responsible for the manufacturing, distribution, marketing, sales, customer service and post-market development of Lucassin.

Tim Wright, CEO of IS Pharma, said:

'We are pleased that Lucassin has been granted Priority Review by the FDA. This marks an important milestone towards obtaining marketing approval in the U.S. where currently no drug is approved for the treatment of hepatorenal syndrome (HRS) Type 1. HRS Type 1 is the development of kidney failure in patients with late-stage liver cirrhosis in the absence of any other cause. It is characterized by rapid onset of renal failure with a high mortality rate that exceeds 80% within three months.'

-End-

[gogoneko] 03/6/2009 19:57

So, see you all in 6-12 months perhaps during which time the share price bobs along again within an unexciting 10-15% trading range!

[daytraders] 03/6/2009 17:20

Broker UPDATE

IS Pharma ( ISPH) a BUY on Initiation of coverage by Finn Cap - Target Price125p

what does Initiation of coverage by Finn Cap actually mean ?

[asp5] 03/6/2009 08:22

gogoneko

I would qualify your analysis by saying they only "owe" money based on certain performance targets being achieved i.e. meeting performance targes will allow them to cover the loans. In addition the performance payments have been structured such that there can only be a max amount paid out in any one year. If performance targets are not met then no payment.

What this also allows the company to do is be smart on how they trigger payments

e.g. approval in EU for haemopressin triggers a 2M payment. Notice how it looks like they have pushed this into this financial year - allowing a full year of haemopressin sales in the 14 terrotries to cover these costs for 09.

[daytraders] 03/6/2009 08:19

how ever you look at it, great results.

[steeplejack] 03/6/2009 08:09

I agree.The key are the eps which are down on weighted average share capital albeit after exceptionals. Enlarged capital is 40m shares i think against the average 30m used in these figures.The cash holding is somewhat flattered by the borrowing drawdown.

That said,all seems to be going very well but they'll be more clarity at the interim figure stage as to how everythings bedding down.I'm happy to hold.

[asp5] 03/6/2009 08:08

Solid results with strong organic growth prospcts at low risk.

14 new territories for haemopressin will be hitting P&L this financial year, plus we have the US approval still to come. In addition from the last set of results they are looking to gain approval for isoplex rollout in europe. On top of this we have "good growth" prospects from the other products such as mysoline, aloxi etc.

This share has every chance to be re-rated as evidence mounts that transformation into a profitable & growth focused company is being achieved.

[gogoneko] 03/6/2009 07:57

The business is strengthening but now they owe £11.5m, £8m of which to be repaid over the next 4/5 years.

On the surface it looks like things are great but the small improvement in net cash over the year (just £0.3m) and the need to extend borrowings by another £3.5m makes me think that the true finances aren't as wonderful as the headline numbers indicate. It's a shame that a fair chunk of the $1.25m payment has been lost on the £526k exceptional charge, perhaps that's why they only repaid £1m during the period.

Still don't see much to get excited about although prospects continue to improve.

[steeplejack] 03/6/2009 07:45

Since the acquisition date, Speciality European Pharma International AG has contributed £0.6m to Group profit. If the acquisition had occurred on 1 April 2008, it is estimated that Group revenue would have been £12.3m and Group profit for the period would have been £2.8m.

[auks] 03/6/2009 07:35

yep, well ahead of all forecasts on all fronts, a strong outlook statement and many products due to launch in the next 12 months...all good; unfortunately cant access the rns on advfn for some reason but can do on digital look

[steeplejack] 03/6/2009 07:26

Profits soar at IS Phama

Business Financial Newswire

IS Pharma said profit before tax was up 70% to £2m (2008: £1.2m) for the year to March 2009.

Revenue was up 73% to £12.2m (2008: £7m) and gross profit up 67% to £7.1m (2008: £4.3m).

Basic earnings per share was 9.1p (2008: 10.3p).

The company had cash of £6m (net cash £2.6m) (2008: £2.3m).

Tim Wright, CEO, said: 'Once again the Company has delivered a strong set of results in line with our growth strategy. We have grown all of our brands resulting in record revenue and profits as well as completing a significant acquisition early in the year.

We have established an international footprint and, following the successful completion of the Mutual Recognition Procedure, are well placed for the launch of Variquel / Haemopressin across 14 new European territories in the coming months.'

[steeplejack] 02/6/2009 16:01

With all those little buy orders peppering the screen today ,i think it's fair to presume that tomorrow's figures will be very acceptable.

[red ninja] 02/6/2009 12:34

Well results are out tomorrow and that will point the direction, be it up or down.

[connello] 02/6/2009 12:03

Some activity over the last week.
Share price seems stuck @76/76.

[red ninja] 12/5/2009 16:40

IS Pharma plc (AIM: ISPH), the international speciality pharmaceutical company, will be announcing its preliminary results for the year ended 31 March 2009 on Wednesday 3 June 2009.